Wells Fargo & Company Begins Coverage on Inozyme Pharma (NASDAQ:INZY)

Wells Fargo & Company initiated coverage on shares of Inozyme Pharma (NASDAQ:INZY – Free Report) in a research note issued to investors on Thursday, Marketbeat Ratings reports. The firm issued an overweight rating and a $14.00 price objective on the stock. Several other research firms have also recently commented on INZY. Needham & Company LLC […]

Leave a Reply

Your email address will not be published.

Previous post Malibu Boats (NASDAQ:MBUU) Downgraded by StockNews.com
Next post Editas Medicine (NASDAQ:EDIT) PT Lowered to $7.00 at Evercore ISI